Table 2 Total HPV-attributable cancer cost (€) in specialist care according to cancer diagnosis, 2014, € 1.00 = NOK 8.357
From: The healthcare costs of treating human papillomavirus-related cancers in Norway
Cancer diagnosis | HPV-related total costs (€) | Base Case Analysis (Hansen et al. 2015) [15] | Sensitivity Analysis (Saraiya et al. 2015) [16] | ||
|---|---|---|---|---|---|
Proportion attributable to HPV (%) | HPV-attributable total costs (€) | Proportion attributable to HPV (%) | HPV-attributable costs (€) | ||
Cervical cancer | 17,213,190 | 100 | 17,213,190 | 90.6 | 15,595,150 |
Vaginal cancer | 462,786 | 81 | 374,857 | 75 | 347,090 |
Vulvar cancer | 3,395,240 | 29 | 984,620 | 68.8 | 2,335,925 |
Penile cancer | 1,623,327 | 47 | 762,964 | 63.3 | 1,027,566 |
Anal cancer | 5,108,420 | 90 | 4,597,578 | 90.6a | 4,628,229 |
Oropharyngeal cancer | 11,736,770 | 57 | 6,689,959 | 67.85a | 7,963,398 |
Total burden of HPV | 39,539,733 | 30,623,167 | 31,897,358 | ||
Proportion of HPV-related total cost (%) | 77.45 | 80.67 | |||